8-K

                        UNITED STATES
             SECURITIES AND EXCHANGE COMMISSION
                   Washington, D. C. 20549


                           FORM 8-K


                         CURRENT REPORT

        Pursuant to Section 13 or 15(d) of the Securities
                      Exchange Act of 1934

   Date of Report (Date of earliest event reported):
                       November 3, 2003

                      HEMACARE CORPORATION
      (Exact Name of Registrant as Specified in its Charter)

                          CALIFORNIA
         (State or other jurisdiction of incorporation)

      000-15223                            95-3280412
(Commission File No.)           (IRS Employer Identification No.)

                     21101 Oxnard Street
                  Woodland Hills, CA 91367
    (Address of principal executive offices and Zip Code)

    Registrant's telephone number, including area code:
                       (818) 226-1968

                             -1-

 2

ITEM 5.	OTHER EVENTS

The text of a press release dated November 3, 2003, issued by
HemaCare Corporation ("HemaCare") announcing the appointment of
Steven Gerber to the Board of Directors a  the appointment Robert
Chilton as Chief Financial Officer, is attached as Exhibit 99.1
hereto and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including the
exhibits, will not be treated as "filed" for the purposes of
Section 18 of the Securities and Exchange Act of 1934 (the
"Exchange  Act") or otherwise subject to the liabilities of
that section.  This information will not be incorporated by
reference into a filing under the Securities Act of 1933, or into
another filing under the Exchange Act, unless that filing
expressly refers to specific information in this report.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number	 Description
- --------------   -----------
99.1	         Press Release issued by HemaCare, dated
                 November 3, 2003


                            SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.

Date:	November 4, 2003	HEMACARE CORPORATION


                                /s/ Judi Irving
                                -------------------------------
				Judi Irving,
                                Chief Executive Officer


                             -2-

EXHIBIT INDEX

Exhibit Number		Description
- --------------          -----------
99.1			Press Release issued by HemaCare, dated
                        November 3, 2003

EX-99

                                [LOGO]

                       N E W S   R E L E A S E


For Immediate Release

Contact:    HemaCare Corporation
            JoAnn Mannise, Director of Investor Relations
            Phone: 877-310-0717
            Email: www.hemacare.com



 HEMACARE ANNOUNCES BOARD AND CHIEF FINANCIAL OFFICER APPOINTMENTS
- -----------------------------------------------------------------------

      Los Angeles, CA, November 3, 2003 - HemaCare Corporation (OTC
Bulletin Board: HEMA.OB) announced today that Steven Gerber has been
named to the Board of Directors. Dr. Gerber, a cardiologist, has
extensive expertise in the securities industry serving most recently as
the head of healthcare research at CIBC World Markets.  He was also a
member of the Board of Directors of Syncor International Corp., a
specialty health services company acquired in January 2003, by Cardinal
Health.  Dr. Gerber fills a board vacancy created by the resignation of
Steven Wallace who had been a member of the Board since 2001.

      The Company has also appointed Robert Chilton as its Chief
Financial Officer.  Mr. Chilton was the Executive Vice President and
Chief Financial Officer of Preferred Health Management, Inc., a
specialty healthcare services company. In addition, Mr. Chilton was the
CFO of OrthAlliance, Inc., an orthodontic practice management company,
during that company's successful IPO.

      Commenting on the appointments, Jay Steffenhagen, Chairman, stated
that, "Steven Gerber and Bob Chilton bring a wealth of finance and
healthcare expertise to our organization.  We are looking forward to
their contributions in shaping the future of the Company."

                      ABOUT HEMACARE CORPORATION

	Founded in 1978, HemaCare is a national provider of blood products and
services and the only publicly traded company engaged in the blood services
industry in the U.S.  HemaCare is licensed by the FDA and accredited by the
American Association of Blood Banks.  The company focuses on providing cost
effective, high quality solutions to the blood-related needs of U.S.
hospitals.

                                   - more -

 2

This press release may contain "forward-looking statements" within the
meaning of the term in the Private Securities Litigation Reform Act of 1995
(Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended).  Additional written or oral
forward-looking statements may be made by the Company from time to time in
filings with the Securities and Exchange Commission or otherwise.
Statements contained herein that are not historical facts are forward-
looking statements pursuant to the safe harbor provisions referenced
above.  Forward-looking statements are inherently subject to risks
and uncertainties some of which cannot be predicted or quantified.
Such risks and uncertainties include, without limitation, the risks
and uncertainties set forth from time to time in reports filed by the
Company with the Securities and Exchange Commission.  Although
the Company believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such expectations
will prove to be correct.  Consequently, future events and actual results
could differ materially from those set forth in, or contemplated by, the
forward-looking statements contained herein.  The Company undertakes no
obligation to publicly release any revision to these forward-looking
statements made to reflect events or circumstances after the date hereof.

                                  ###